Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alliance Pharma PLC (GB:APH)
LSE:APH
Holding GB:APH?
Track your performance easily
APH Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range24.55p - 50.26p
Previous Close46.1p
Volume324.85K
Average Volume (3M)997.44K
Market Cap
£249.20M
Enterprise Value355.06M
Total Cash (Recent Filing)£31.71M
Total Debt (Recent Filing)£137.58M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 25, 2025EPS Estimate
£0.03Last Dividend Ex-Date
Jun 22, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding540,565,539
10 Day Avg. Volume569,045
30 Day Avg. Volume997,443
Standard Deviation0.10
R-Squared0.09
Alpha-0.00405
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)90.39
Price to Sales (P/S)1.47
Price to Cash Flow (P/CF)8.10
P/FCF Ratio6.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
51.00pPrice Target Upside10.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Alliance Pharma News
PremiumCompany Announcements
Alliance Pharma Sees Major Share Ownership Shift
PremiumCompany Announcements
Alliance Pharma Reports Steady Growth in 2024
PremiumCompany Announcements
Alliance Pharma Announces Upcoming Financial Results
PremiumCompany Announcements
Alliance Pharma Confronts AGM Dissent
PremiumCompany Announcements
Alliance Pharma Sustains Growth Amidst Challenges
PremiumCompany Announcements
Slater Investments Boosts Stake in Alliance Pharma
PremiumCompany Announcements
Alliance Pharma Stake Shifts with Slater Investments
PremiumCompany Announcements
Slater Investments Ups Stake in Alliance PharmaBulls Say, Bears Say
Bulls Say
Debt ManagementNet debt and leverage metrics have improved slightly and are projected to decrease further, with the company aiming for a leverage target of around 1.5x.
Financial PerformanceKelo-Cote franchise revenues showed impressive growth, increasing by 14.2% to £29.2 million, significantly outpacing the market growth in China.
Revenue GrowthThe company's 1H24 results align with previous updates, showcasing a revenue increase of 2.9% and a constant exchange rate growth of 5.0%.
Bears Say
Earnings GrowthThe lack of earnings growth and the increased risk profile of the business through over-reliance on Kelo-Cote provides reasons for the discounted valuation.
Revenue DeclineNizoral revenues were down 25% to £8.3m, impacted by destocking following a build in inventory ahead of the planned move to a new manufacturer.
Stock ValuationWith a flat earnings year and the stock trading on 9.5x PE and 7.3x EV/EBITDA, analyst prefers to stay on the sidelines.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.53% Mutual Funds
― Other Institutional Investors
97.41% Public Companies and
Individual Investors
APH FAQ
What was Alliance Pharma PLC’s price range in the past 12 months?
Alliance Pharma PLC lowest share price was 24.55p and its highest was 50.26p in the past 12 months.
What is Alliance Pharma PLC’s market cap?
Currently, no data Available
When is Alliance Pharma PLC’s upcoming earnings report date?
Alliance Pharma PLC’s upcoming earnings report date is Mar 25, 2025 which is in 92 days.
How were Alliance Pharma PLC’s earnings last quarter?
Alliance Pharma PLC released its earnings results on Sep 30, 2024. The company reported 0.018p earnings per share for the quarter, beating the consensus estimate of N/A by 0.018p.
Is Alliance Pharma PLC overvalued?
According to Wall Street analysts Alliance Pharma PLC’s price is currently Undervalued.
Does Alliance Pharma PLC pay dividends?
Alliance Pharma PLC pays a Annually dividend of 1.183p which represents an annual dividend yield of N/A. See more information on Alliance Pharma PLC dividends here
What is Alliance Pharma PLC’s EPS estimate?
Alliance Pharma PLC’s EPS estimate is £0.03.
How many shares outstanding does Alliance Pharma PLC have?
Alliance Pharma PLC has 540,565,550 shares outstanding.
What happened to Alliance Pharma PLC’s price movement after its last earnings report?
Alliance Pharma PLC reported an EPS of 0.018p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.181%.
Which hedge fund is a major shareholder of Alliance Pharma PLC?
Currently, no hedge funds are holding shares in GB:APH
---
Alliance Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.53%
12-Months-Change
Fundamentals
Return on Equity
-13.44%
Trailing 12-Months
Asset Growth
-22.46%
Trailing 12-Months
Company Description
Alliance Pharma PLC
Alliance Pharma PLC is a player in the healthcare market. The company's business includes acquisition, marketing, and distribution of pharmaceutical products. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol.
---
APH Stock 12 Month Forecast
Average Price Target
51.00p
▲(10.63% Upside)
Technical Analysis
Advanced Medical Solutions
―
Eco Animal Health
―
Hikma Pharmaceuticals
―
Scancell Holdings
―
Best Analysts Covering APH
1 Year
1 Year Success Rate
3/15 ratings generated profit
1 Year Average Return
-21.40%
assigned a buy rating 2 months ago
Copying Charles Weston's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -21.40% per trade.
---